Bio-engineered cell membrane nanovesicles as precision theranostics for perihilar cholangiocarcinoma
Source abstract
Abstract
Perihilar cholangiocarcinoma (PHCC) presents a formidable challenge due to its occult anatomic location, aggressive growth, insensitivity to conventional chemotherapy, and poor prognosis. Herein, we engineered a human epidermal growth factor receptor 2 (HER2) affibody to the surface of cell membrane nanovesicles (A-NVs) in a ligand-oriented manner and loaded them with indocyanine green (ICG) as precision theranostics for PHCC treatment. The A-NVs@ICG were prepared and exhibited satisfactory targeting effects in HER2-overexpressing PHCC cells. In vivo fluorescence and photoacoustic imaging demonstrated that A-NVs@ICG promoted the accumulation of ICG in PHCC tissue, leading to enhanced tumor regression and improved anti-cancer effects when combined with photoirradiation. Therefore, bio-engineered A-NVs@ICG represent a promising nanotheranostic agent for PHCC with potential for clinical translation.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hepatobiliary Surgery
Xiang'an Hospital of Xiamen University
School of Medicine
Xiamen University
Xiamen 361102
State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine
School of Public Health
China
Funding
National Basic Research Program of China · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities · Program for New Century Excellent Talents in University
References (26)
Show source-provided references
1. Waseem · Ann. Hepatol. · 2017 · 16 · 13310.5604/16652681.1226927 ↗
2. Blechacz · Gut Liver · 2017 · 11 · 1310.5009/gnl15568 ↗
3. Cillo · Liver Int. · 2019 · 39 · 14310.1111/liv.14089 ↗
4. Pitt · Ann. Surg. · 2017 · 221 · 78810.1097/00000658-199506000-00017 ↗
5. Lee · J. Gastroenterol. Hepatol. · 2016 · 31 · 49310.1111/jgh.13059 ↗
6. Leng · Oncotargets Ther. · 2017 · 10 · 225710.2147/OTT.S131873 ↗
7. Mott · Am. J. Gastroenterol. · 2007 · 102 · 217110.1111/j.1572-0241.2007.01394.x ↗
8. Chen · Nat. Rev. Mater. · 2017 · 2 · 1
9. Ban · Biomater Sci. · 2017 · 5 · 19010.1039/C6BM00600K ↗
10. Huang · Biomater. Sci. · 2017 · 5 · 151210.1039/C7BM00302A ↗
11. Chu · Angew. Chem., Int. Ed. · 2018 · 58 · 26910.1002/anie.201812482 ↗
12. Xuan · Angew. Chem., Int. Ed. · 2018 · 57 · 157
13. Chen · ACS Nano · 2018 · 12 · 564610.1021/acsnano.8b01440 ↗
14. Zhang · Proc. Natl. Acad. Sci. U. S. A. · 2015 · 45 · E612910.1073/pnas.1505799112 ↗
15. Chen · ACS Nano · 2016 · 10 · 1004910.1021/acsnano.6b04695 ↗
16. Lv · Nano Lett. · 2019 · 19 · 299310.1021/acs.nanolett.9b00145 ↗
17. Zhang · Adv. Mater. · 2018 · 30 · 170535010.1002/adma.201705350 ↗
18. Liu · Adv. Mater. · 2019 · 31 · 180829410.1002/adma.201808294 ↗
19. Shi · J. Controlled Release · 2020 · 320 · 30410.1016/j.jconrel.2020.01.054 ↗
20. Liu · Biomater. Sci. · 2019 · 7 · 170510.1039/C8BM01541D ↗
21. Chow · Anticancer Res. · 1995 · 15 · 1055
22. Iqbal · Mol. Biol. Int. · 2014 · 14 · 85
23. Sohal · Crit. Rev. Oncol. Hematol. · 2016 · 107 · 11110.1016/j.critrevonc.2016.08.013 ↗
24. Lin · Nano Res. · 2020 · 13 · 23810.1007/s12274-019-2606-2 ↗
25. Wang · Adv. Sci. · 2018 · 5 · 180056410.1002/advs.201800564 ↗
26. Zhong · Oncol. Lett. · 2015 · 10 · 141610.3892/ol.2015.3391 ↗